The Lung Cancer Liquid Biopsy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations. According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Lung Cancer Liquid Biopsy market size is estimated to be worth US$ 438 million in 2021 and is forecast to a readjusted size of USD 1056.2 million by 2028 with a CAGR of 13.4% during review period. Hospitals accounting for % of the Lung Cancer Liquid Biopsy global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Exosomes and RNA segment is altered to a % CAGR between 2022 and 2028. Global key companies of Lung Cancer Liquid Biopsy include RainDanceTechnologies, Biocartis, Qiagen, Guardant Health, and MDxHealth, etc. In terms of revenue, the global top four players hold a share over % in 2021. Market segmentation Lung Cancer Liquid Biopsy market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets. Market segment by Type, covers Exosomes and RNA CTCs and ctDNA Market segment by Application, can be divided into Hospitals Clinics Others Market segment by players, this report covers RainDanceTechnologies Biocartis Qiagen Guardant Health MDxHealth Pathway Genomics NeoGenomics Laboraories Sysmex Inostics Cynvenio Menarini Silicon Biosystems Adaptive Biotechnologies Biocept Angle plc Market segment by regions, regional analysis covers North America (United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, Italy, and Rest of Europe) Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific) South America (Brazil, Argentina, Rest of South America) Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa) The content of the study subjects, includes a total of 12 chapters: Chapter 1, to describe Lung Cancer Liquid Biopsy product scope, market overview, market opportunities, market driving force and market risks. Chapter 2, to profile the top players of Lung Cancer Liquid Biopsy, with revenue, gross margin and global market share of Lung Cancer Liquid Biopsy from 2019 to 2022. Chapter 3, the Lung Cancer Liquid Biopsy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast. Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028. Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Lung Cancer Liquid Biopsy market forecast, by regions, type and application, with revenue, from 2023 to 2028. Chapter 11 and 12, to describe Lung Cancer Liquid Biopsy research findings and conclusion, appendix and data source.
1 Market Overview 1.1 Product Overview and Scope of Lung Cancer Liquid Biopsy 1.2 Classification of Lung Cancer Liquid Biopsy by Type 1.2.1 Overview: Global Lung Cancer Liquid Biopsy Market Size by Type: 2017 Versus 2021 Versus 2028 1.2.2 Global Lung Cancer Liquid Biopsy Revenue Market Share by Type in 2021 1.2.3 Exosomes and RNA 1.2.4 CTCs and ctDNA 1.3
